Hong Kong, 21 March 2023
Opharmic Signs Development Agreement with Rohto Pharmaceutical for Ultrasound Cell Stimulation in Regenerative Medicine
Opharmic Technology (HK) Limited is pleased to announce our commercial collaboration with Rohto Advance Research (ARHK), a remarkable subsidiary of the leading Japanese pharmaceutical company in the field of regenerative medicine. With common goals aligned, Opharmic and ARHK will strive to work towards providing patient-orientated innovative solutions through upcoming research and development collaboration. This collaboration focuses on advancing novel ultrasound-mediated cell stimulation technology and devices under Opharmic’s MeticStim® platform for regenerative medicine research
MeticStim® is Opharmic’s proprietary platform that delivers targeted ultrasound energy to cells or tissues to stimulate specific cellular responses without chemical alteration or invasive procedures. Building on the company’s broader ultrasound expertise (including MeticTouch® for ocular drug delivery), MeticStim® offers a versatile, non-invasive tool that can potentially optimize cell therapies, enhance regenerative processes, and support cell therapy applications.
Sharing the common excitement upon the promising results and co-filed patent from the 1st joint research project, both Opharmic and ARHK are keen on the opportunity to explore the application of Opharmic’s novel ultrasound technology for Rohto’s exclusive stem cell research.
As Opharmic’s first commercial collaboration in regenerative medicine, we are honoured to be partnering with one of the strongest field leader. In 2017, Rohto started its first clinical trial using allogenic adipose-derived mesenchymal stromal cells against liver cirrhosis. Currently, Rohto are performing multiple clinical trials against various target indications in Japan. Read more of Rohto’s development in regenerative medicine here.
Over the years, Opharmic has grown to becoming a trustworthy partner and solution provider. With this exclusive opportunity with Rohto, we look forward to continue our mission in promoting medical innovations via our novel ultrasound technology platform.
Opharmic Technology